Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2Phase 2/3 1

Status

Active not recruiting 11Recruiting 10Completed 7Unknown 4Withdrawn 3Terminated 3Not yet recruiting 1Approved for marketing 1

Sponsor Class

OTHER 4INDUSTRY 3

Study Type

Interventional 5Observational 2

Sponsor

Cancer Type

NET 7Endocrine 7Gastrointestinal 1

Conditions

Neuroendocrine Tumors 7Somatostatinoma 1Somatostatin Receptor-positive Neuroendocrine Tumor 1Somatostatin Receptor-positive GEP-NET 1Small Cell Lung Carcinoma 1Neuroblastoma 1Gastro-enteropancreatic neuroendocrine tumor 1

Interventions

Everolimus 17lutetium Lu 177 dotatate 7Octreotide 7pasireotide 6lanreotide 6gallium Ga 68 dotatate 5Temozolomide 5Sunitinib 5Positron Emission Tomography Computed Tomography 5surufatinib 4pembrolizumab 4Sorafenib 4Data Collection 4Carboplatin 43-Iodobenzylguanidine 4Positron-Emission Tomography 3Nivolumab 3Etoposide 3Capecitabine 390Y-octreotide, DOTA-Tyr(3)- 3pentetreotide 2pazopanib 2lenvatinib 2fosbretabulin 2fluorodopa F 18 2cabozantinib 2avelumab 2arginyllysine 2Single Photon Emission Computed Tomography Computed Tomography 2Pemetrexed 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
Completed × Neuroendocrine Tumors × lutetium Lu 177 dotatate × Clear all
NCT04727723 2026-05-04

REAL-LU

Novartis

Completed
164 enrolled
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Neuroendocrine Tumors

NCT04385992 2023-06-27

NeoLuPaNET

IRCCS San Raffaele

Phase 2 Completed
31 enrolled
EndocrineNET

Neuroendocrine Tumors

NCT05816720 2023-04-18

Retrospective Analysis of Patients Re-treated With Lutetium-177 DOTATATE (Lutathera®)

Novartis

Completed
31 enrolled
EndocrineNET

Neuroendocrine Tumors

NCT01237457 2023-03-20

177Lutetium-DOTA-Octreotate Therapy in Somatostatin Receptor-Expressing Neuroendocrine Neoplasms

Excel Diagnostics and Nuclear Oncology Center

Phase 2 Completed
143 enrolled
EndocrineNET

Neuroendocrine Tumors

NCT01842165 2022-11-10

LUMEN

Jules Bordet Institute

Phase 3 Completed
37 enrolled
EndocrineNET

Neuroendocrine Tumors

NCT03590119 2022-11-08

LUTIA

UMC Utrecht

Phase 2/3 Completed
26 enrolled
EndocrineNET

Neuroendocrine Tumors

NCT01578239 2022-04-04

NETTER-1

Advanced Accelerator Applications

Phase 3 Completed
231 enrolled 16 charts 2 FDA
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡